{"slug":"edwards-lifesciences","name":"에드워즈 라이프사이언스","name_en":"Edwards Lifesciences Corporation","ticker":"EW","updated_at":"2026-09-11T23:11:32.677063+00:00","canonical":"https://valuechain.wiki/edwards-lifesciences","citable":"밸류체인 그래프 기준 에드워즈 라이프사이언스의 직접 연결 기업은 3곳(관계 기준 공급 0·매출 0·투자 3)이고, 사슬을 2차까지 넓히면 19곳에 닿는다. 링크의 근거 출처는 12건이며 그중 1차공시가 6건이다 (valuechain.wiki, 2026-09-11 기준).","citable_en":"Per the valuechain.wiki graph, Edwards Lifesciences Corporation is directly linked to 3 companies (0 supply, 0 revenue, 3 investment relationships) and reaches 19 companies within two hops; the links are backed by 12 dated sources, 6 of them primary filings (as of 2026-09-11).","kicker":"구조적 심장 치료기기","kicker_en":"Structural heart devices","lead":"에드워즈 라이프사이언스는 병원과 공공 의료조달망에 TAVR, TMTT, 수술용 구조적 심장 치료기기를 판매한다. 동물 조직, 수지, 화학재료, 전자부품, 금속과 의료기기 부품을 외부 공급사에서 조달하고 신기술 기업에 투자한다.","lead_en":"Edwards Lifesciences sells TAVR, TMTT, and surgical structural-heart devices to hospitals and public healthcare procurement networks. It buys animal tissue, resins, chemicals, electronics, metals, and medical-device components from outside suppliers and invests in emerging technologies.","categories":[{"key":"medical-devices-supplies","ko":"의료기기·의료용품","en":"Medical Devices & Supplies","theme":"life-sciences","theme_ko":"바이오·헬스","theme_en":"Biopharma & Life Sciences","theme_kind":"sector","primary":true}],"segments":{"parts":[{"name":"경피적 대동맥판막 치환술(TAVR)","note":"FY2025 매출 44억 8,770만 달러"},{"name":"경피적 승모판·삼첨판 치료(TMTT)","note":"FY2025 매출 5억 5,060만 달러"},{"name":"수술용 구조적 심장","note":"FY2025 매출 10억 2,930만 달러"}],"total":"FY2025 총매출 60억 6,760만 달러","track":"C"},"segments_en":{"parts":[{"name":"Transcatheter Aortic Valve Replacement (TAVR)","note":"FY2025 revenue of $4.4877 billion"},{"name":"Transcatheter Mitral and Tricuspid Therapies (TMTT)","note":"FY2025 revenue of $550.6 million"},{"name":"Surgical Structural Heart","note":"FY2025 revenue of $1.0293 billion"}],"total":"FY2025 total revenue of $6.0676 billion"},"returns_yearly":{"2021":42,"2022":-42.4,"2023":2.2,"2024":-2.9,"2025":15.2,"2026":5.5},"return_asof":"2026-09-04","value_chain":{"leading":[],"benefiting":[{"slug":"state-street","name":"스테이트 스트리트","name_en":"State Street Corporation","tier":1,"returns_yearly":{"2021":31,"2022":-13.8,"2023":3.5,"2024":30.2,"2025":35.5,"2026":38.8}},{"slug":"becton-dickinson","name":"벡톤 디킨슨","name_en":"Becton, Dickinson and Company","tier":1,"returns_yearly":{"2021":1.9,"2022":5.1,"2023":-2.7,"2024":-5.4,"2025":-12.6,"2026":22.8}},{"slug":"blackrock","name":"BlackRock","name_en":"BlackRock","tier":1,"returns_yearly":{"2021":29.4,"2022":-20.4,"2023":17.9,"2024":29.3,"2025":6.6,"2026":2.8}},{"slug":"marathon-petroleum","name":"마라톤 페트롤리엄","name_en":"Marathon Petroleum Corporation","tier":2,"returns_yearly":{"2021":61,"2022":86.6,"2023":30.5,"2024":-4.1,"2025":19.2,"2026":183}},{"slug":"targa-resources","name":"타가 리소시스","name_en":"Targa Resources Corp.","tier":2,"returns_yearly":{"2021":100.1,"2022":43.7,"2023":21,"2024":110.1,"2025":5.7,"2026":59.5}},{"slug":"jabil","name":"자빌","name_en":"Jabil","tier":2,"returns_yearly":{"2021":66.4,"2022":-2.5,"2023":87.4,"2024":13.3,"2025":58.7,"2026":36.3}},{"slug":"altria","name":"알트리아","name_en":"Altria Group, Inc.","tier":2,"returns_yearly":{"2021":24.2,"2022":4.4,"2023":-3.7,"2024":40.8,"2025":18.2,"2026":30.3}},{"slug":"ross-stores","name":"로스 스토어스","name_en":"Ross Stores","tier":2,"returns_yearly":{"2021":-6,"2022":2.9,"2023":20.6,"2024":10.4,"2025":20.4,"2026":28.6}},{"slug":"oneok","name":"원오크","name_en":"ONEOK, Inc.","tier":2,"returns_yearly":{"2021":64.7,"2022":18.9,"2023":13.2,"2024":50.1,"2025":-22.9,"2026":26.8}},{"slug":"elevance-health","name":"엘레반스 헬스","name_en":"Elevance Health, Inc.","tier":2,"returns_yearly":{"2021":46.1,"2022":11.8,"2023":-6.9,"2024":-20.7,"2025":-3.1,"2026":17.4}},{"slug":"old-dominion","name":"올드 도미니언","name_en":"Old Dominion Freight Line, Inc.","tier":2,"returns_yearly":{"2021":84.1,"2022":-20.5,"2023":43.5,"2024":-12.5,"2025":-10.5,"2026":16.5}},{"slug":"incyte","name":"인사이트","name_en":"Incyte Corporation","tier":2,"returns_yearly":{"2021":-15.6,"2022":9.4,"2023":-21.8,"2024":10,"2025":43,"2026":14.2}},{"slug":"american-water-works","name":"아메리칸 워터 웍스","name_en":"American Water Works","tier":2,"returns_yearly":{"2021":24.8,"2022":-17.9,"2023":-11.7,"2024":-3.5,"2025":7.4,"2026":10.1}},{"slug":"hubbell-incorporated","name":"허벨","name_en":"Hubbell Incorporated","tier":2,"returns_yearly":{"2021":35.6,"2022":15.1,"2023":42.4,"2024":28.9,"2025":7.4,"2026":4.7}},{"slug":"microsoft","name":"마이크로소프트","name_en":"Microsoft","tier":2,"returns_yearly":{"2021":52.5,"2022":-28,"2023":58.2,"2024":12.9,"2025":15.6,"2026":4}},{"slug":"edison-international","name":"에디슨 인터내셔널","name_en":"Edison International","tier":2,"returns_yearly":{"2021":13.6,"2022":-2.6,"2023":17.4,"2024":15.2,"2025":-20.4,"2026":-1.7}},{"slug":"public-service-enterprise-group","name":"퍼블릭 서비스 엔터프라이즈 그룹","name_en":"Public Service Enterprise Group Incorporated","tier":2,"returns_yearly":{"2021":18.3,"2022":-5.1,"2023":3.6,"2024":42.6,"2025":-1.9,"2026":-6.7}},{"slug":"steris","name":"스테리스","name_en":"STERIS plc","tier":2,"returns_yearly":{"2021":29.5,"2022":-23.4,"2023":20.2,"2024":-5.6,"2025":24.3,"2026":-14.7}},{"slug":"zoetis","name":"조에티스","name_en":"Zoetis Inc.","tier":2,"returns_yearly":{"2021":48.3,"2022":-39.5,"2023":35.9,"2024":-16.6,"2025":-21.8,"2026":-39.6}},{"slug":"seagate","name":"Seagate","name_en":"Seagate Technology","tier":3,"returns_yearly":{"2021":87.5,"2022":-51.4,"2023":69.1,"2024":4.1,"2025":225.3,"2026":209.1}},{"slug":"amd","name":"AMD","name_en":"AMD","tier":3,"returns_yearly":{"2021":56.9,"2022":-55,"2023":127.6,"2024":-18.1,"2025":77.3,"2026":183.9}},{"slug":"nebius","name":"Nebius","name_en":"Nebius Group","tier":3,"returns_yearly":{"2025":202.2,"2026":170.5}},{"slug":"marvell","name":"Marvell","name_en":"Marvell","tier":3,"returns_yearly":{"2021":84.6,"2022":-57.5,"2023":63.7,"2024":83.8,"2025":-22.8,"2026":163.4}},{"slug":"intel","name":"Intel","name_en":"Intel","tier":3,"returns_yearly":{"2021":6.1,"2022":-46.6,"2023":94.6,"2024":-59.6,"2025":84,"2026":159.6}},{"slug":"western-digital","name":"Western Digital","name_en":"Western Digital","tier":3,"returns_yearly":{"2021":17.7,"2022":-51.6,"2023":66,"2024":13.9,"2025":283.7,"2026":130.9}},{"slug":"astera-labs","name":"Astera Labs","name_en":"Astera Labs","tier":3,"returns_yearly":{"2025":25.6,"2026":105.7}},{"slug":"wiwynn","name":"Wiwynn","name_en":"Wiwynn","tier":3,"returns_yearly":{"2021":24.7,"2022":-22.3,"2023":206.4,"2024":3.5,"2025":64.4,"2026":92.3}},{"slug":"vertiv","name":"Vertiv","name_en":"Vertiv","tier":3,"returns_yearly":{"2021":33.8,"2022":-45.3,"2023":251.8,"2024":136.8,"2025":42.8,"2026":73.2}},{"slug":"ge-vernova","name":"GE Vernova","name_en":"GE Vernova","tier":3,"returns_yearly":{"2025":99,"2026":54}},{"slug":"tsmc","name":"TSMC","name_en":"TSMC","tier":3,"returns_yearly":{"2021":12.1,"2022":-36.7,"2023":42.3,"2024":92.6,"2025":55.9,"2026":50.3}},{"slug":"occidental-petroleum","name":"옥시덴탈 페트롤리엄","name_en":"Occidental Petroleum","tier":3,"returns_yearly":{"2021":67.7,"2022":119.1,"2023":-4.1,"2024":-15.9,"2025":-14.9,"2026":48.2}},{"slug":"arista","name":"Arista Networks","name_en":"Arista Networks","tier":3,"returns_yearly":{"2021":97.9,"2022":-15.6,"2023":94.1,"2024":87.7,"2025":18.5,"2026":47.9}},{"slug":"sumitomo-electric","name":"Sumitomo Electric","name_en":"Sumitomo Electric","tier":3,"returns_yearly":{"2021":11.4,"2022":6.3,"2023":30.8,"2024":52.9,"2025":139,"2026":43.2}},{"slug":"super-micro","name":"Super Micro","name_en":"Super Micro","tier":3,"returns_yearly":{"2021":38.8,"2022":86.8,"2023":246.2,"2024":7.2,"2025":-4,"2026":43}},{"slug":"archer-daniels-midland","name":"아처 대니얼스 미들랜드","name_en":"Archer-Daniels-Midland Company","tier":3,"returns_yearly":{"2021":37.3,"2022":40,"2023":-20.4,"2024":-27.5,"2025":18.2,"2026":41.8}},{"slug":"caterpillar","name":"Caterpillar","name_en":"Caterpillar","tier":3,"returns_yearly":{"2021":16,"2022":18.6,"2023":25.9,"2024":24.7,"2025":60.3,"2026":40.6}},{"slug":"ciena","name":"Ciena","name_en":"Ciena","tier":3,"returns_yearly":{"2021":45.6,"2022":-33.8,"2023":-11.7,"2024":88.4,"2025":175.8,"2026":37.3}},{"slug":"equinix","name":"Equinix","name_en":"Equinix","tier":3,"returns_yearly":{"2021":20.3,"2022":-21.1,"2023":25.4,"2024":19.5,"2025":-16.9,"2026":37.3}},{"slug":"eaton","name":"Eaton","name_en":"Eaton","tier":3,"returns_yearly":{"2021":46.7,"2022":-7.2,"2023":56.2,"2024":39.5,"2025":-2.8,"2026":36}},{"slug":"philip-morris-international","name":"필립 모리스 인터내셔널","name_en":"Philip Morris International Inc.","tier":3,"returns_yearly":{"2021":20.8,"2022":12.3,"2023":-1.9,"2024":34.3,"2025":38,"2026":28.7}},{"slug":"cvs-health","name":"CVS 헬스","name_en":"CVS Health","tier":3,"returns_yearly":{"2021":54.9,"2022":-7.6,"2023":-12.5,"2024":-40.8,"2025":84.3,"2026":24.7}},{"slug":"digital-realty","name":"Digital Realty","name_en":"Digital Realty","tier":3,"returns_yearly":{"2021":30.7,"2022":-41,"2023":39.9,"2024":35.9,"2025":-10.1,"2026":23.4}},{"slug":"nvidia","name":"NVIDIA","name_en":"NVIDIA","tier":3,"returns_yearly":{"2021":125.5,"2022":-50.3,"2023":239,"2024":171.2,"2025":38.9,"2026":23.2}},{"slug":"quanta","name":"Quanta","name_en":"Quanta Computer","tier":3,"returns_yearly":{"2021":22.2,"2022":-12.8,"2023":254.5,"2024":12.7,"2025":8.9,"2026":21.2}},{"slug":"federal-realty-investment-trust","name":"페더럴 리얼티 인베스트먼트 트러스트","name_en":"Federal Realty Investment Trust","tier":3,"returns_yearly":{"2021":66,"2022":-22.7,"2023":6.6,"2024":12.1,"2025":-5.9,"2026":19.8}},{"slug":"credo","name":"크레도","name_en":"Credo Technology","tier":3,"returns_yearly":{"2023":46.3,"2024":245.2,"2025":114.1,"2026":18.5}},{"slug":"abb","name":"ABB","name_en":"ABB","tier":3,"returns_yearly":{"2021":23.9,"2022":7.3,"2023":18.9,"2024":39,"2025":36.1,"2026":18.4}},{"slug":"iren","name":"IREN","name_en":"IREN","tier":3,"returns_yearly":{"2022":-92.3,"2023":472,"2024":37.3,"2025":284.6,"2026":18.3}},{"slug":"foxconn","name":"Foxconn","name_en":"Foxconn (Hon Hai)","tier":3,"returns_yearly":{"2021":-5.1,"2022":2.8,"2023":7.8,"2024":80.1,"2025":26.9,"2026":16.3}},{"slug":"coreweave","name":"CoreWeave","name_en":"CoreWeave","tier":3,"returns_yearly":{"2026":14.6}},{"slug":"kuraray","name":"구라레","name_en":"Kuraray","tier":3,"returns_yearly":{"2021":-4.9,"2022":8.7,"2023":50.1,"2024":51,"2025":-24.7,"2026":12.5}},{"slug":"amazon","name":"아마존","name_en":"Amazon","tier":3,"returns_yearly":{"2021":2.4,"2022":-49.6,"2023":80.9,"2024":44.4,"2025":5.2,"2026":12}},{"slug":"schneider-electric","name":"Schneider Electric","name_en":"Schneider Electric","tier":3,"returns_yearly":{"2021":25.9,"2022":1.6,"2023":25.8,"2024":36.1,"2025":0.5,"2026":11.7}},{"slug":"simon-property-group","name":"사이먼 프로퍼티 그룹","name_en":"Simon Property Group","tier":3,"returns_yearly":{"2021":95.7,"2022":-21.9,"2023":29.2,"2024":26.9,"2025":12.9,"2026":11.4}},{"slug":"cummins","name":"Cummins","name_en":"Cummins","tier":3,"returns_yearly":{"2021":-1.7,"2022":14.1,"2023":1.7,"2024":48.9,"2025":49.4,"2026":11}},{"slug":"automatic-data-processing","name":"오토매틱 데이터 프로세싱","name_en":"Automatic Data Processing, Inc.","tier":3,"returns_yearly":{"2021":42.6,"2022":-1.3,"2023":-0.2,"2024":28.4,"2025":-10.2,"2026":9.6}},{"slug":"3m","name":"3M","name_en":"3M Company","tier":3,"returns_yearly":{"2021":4.9,"2022":-29.6,"2023":-3.3,"2024":46.1,"2025":26.4,"2026":6.8}},{"slug":"legrand","name":"르그랑","name_en":"Legrand","tier":3,"returns_yearly":{"2021":20.3,"2022":-7.1,"2023":12.8,"2024":11.9,"2025":39.3,"2026":6.1}},{"slug":"nxp","name":"NXP반도체","name_en":"NXP Semiconductors","tier":3,"returns_yearly":{"2021":44.8,"2022":-29.2,"2023":48.4,"2024":-8,"2025":6.4,"2026":5.9}},{"slug":"expedia-group","name":"익스피디아 그룹","name_en":"Expedia Group, Inc.","tier":3,"returns_yearly":{"2021":36.5,"2022":-51.5,"2023":73.3,"2024":22.8,"2025":53.3,"2026":5.8}},{"slug":"wec-energy-group","name":"WEC 에너지 그룹","name_en":"WEC Energy Group","tier":3,"returns_yearly":{"2021":8.7,"2022":-0.5,"2023":-7,"2024":16.1,"2025":16,"2026":3.1}},{"slug":"cheryong-electric","name":"제룡전기","name_en":"Cheryong Electric","tier":3,"returns_yearly":{"2021":-14.1,"2022":141.8,"2023":89.3,"2024":178.6,"2025":-9.3,"2026":-1}},{"slug":"taihan-cable-solution","name":"대한전선","name_en":"Taihan Cable & Solution","tier":3,"returns_yearly":{"2021":59.3,"2022":-0.7,"2023":-36,"2024":40.6,"2025":124.6,"2026":-4.4}},{"slug":"apollo-global-management","name":"아폴로 글로벌 매니지먼트","name_en":"Apollo Global Management","tier":3,"returns_yearly":{"2021":53.2,"2022":-9.6,"2023":49.4,"2024":79.9,"2025":-11.1,"2026":-6.5}},{"slug":"lg-chem","name":"LG화학","name_en":"LG Chem","tier":3,"returns_yearly":{"2021":-29,"2022":9.7,"2023":-36.6,"2024":-45.3,"2025":31.2,"2026":-8.6}},{"slug":"brookfield","name":"Brookfield","name_en":"Brookfield Asset Management Ltd.","tier":3,"returns_yearly":{"2023":45.6,"2024":39.7,"2025":-0.2,"2026":-9.7}},{"slug":"ionq","name":"IonQ","name_en":"IonQ","tier":3,"returns_yearly":{"2022":-79.3,"2023":259.1,"2024":237.1,"2025":7.4,"2026":-11.9}},{"slug":"tesla","name":"Tesla","name_en":"Tesla","tier":3,"returns_yearly":{"2021":49.8,"2022":-65,"2023":101.7,"2024":62.5,"2025":11.4,"2026":-14.9}},{"slug":"constellation-energy","name":"Constellation Energy","name_en":"Constellation Energy","tier":3,"returns_yearly":{"2023":37.2,"2024":92.7,"2025":58.8,"2026":-15.3}},{"slug":"take-two-interactive","name":"테이크투 인터랙티브","name_en":"Take-Two Interactive Software, Inc.","tier":3,"returns_yearly":{"2021":-14.5,"2022":-41.4,"2023":54.6,"2024":14.4,"2025":39.1,"2026":-16.6}},{"slug":"openai","name":"OpenAI","name_en":"OpenAI","tier":3,"returns_yearly":null}],"analysis":"구조적 심장 치료기기 기업. 2026년 +5.5%다. 수요·공급 연결은 확인되지만 상장 상대 수익률 데이터는 제한적이다.","analysis_en":"Edwards Lifesciences Corporation operates across Structural heart devices. It is +5.5% in 2026. Its demand and supply links are known, but listed-counterparty return data is limited. It buys animal tissue, resins, chemicals, electronics, metals, and medical-device components from outside suppliers and invests in emerging technologies.","analysis_asof":"2026-09-04"},"edges":[{"direction":"investor","counterparty":"벡톤 디킨슨","counterparty_slug":"becton-dickinson","confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2025-11-25","basis":"에드워즈 라이프사이언스 Critical Care 사업 인수의 최종 이전대가 공정가치","value":3914000000,"period":"acquisition completed 2024-09-03","basis_en":"Final fair value of consideration for the Edwards Lifesciences Critical Care acquisition","qualifier":null},"note":"에드워즈 라이프사이언스는 2024년 9월 Critical Care 사업을 BD에 매각해 BD Advanced Patient Monitoring으로 편입됐으며, BD의 2025년 10-K에 기록된 최종 이전대가 공정가치는 39억1,400만 달러다.","note_en":"Edwards Lifesciences sold its Critical Care business to BD in September 2024, after which it was renamed BD Advanced Patient Monitoring, and the final fair value of consideration recorded in BD's 2025 Form 10-K was $3.914 billion.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2025-11-25","url":"https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm","title":"BECTON DICKINSON & CO 10-K (2025-11-25)","title_en":"BECTON DICKINSON & CO 10-K (2025-11-25)","excerpt":"공시는 인수 이전대가의 공정가치를 39억1,400만 달러로 기록했다.","excerpt_en":"The fair value of consideration transferred in connection with the acquisition was $3.914 billion."},{"stance":"confirms","publisher":"MedTech Dive","publisher_en":"MedTech Dive","kind":"analysis","lang":"en","published_at":"2024-09-05","url":"https://www.medtechdive.com/news/edwards-layoffs-500-jobs-critical-care-sale/726151/","title":"Critical Care 매각 후 에드워즈 500명 이상 감원","title_en":"Edwards Cuts More Than 500 Employees After Critical Care Sale","excerpt":"산업 분석은 에드워즈가 같은 주에 Critical Care 사업을 BD에 42억 달러에 매각 완료했다고 확인했다.","excerpt_en":"Edwards completed the $4.2 billion sale of its critical care business to BD."}]},{"direction":"investment","counterparty":"JenaValve Technology","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2026-02-25","basis":"JenaValve 전환사채 투자액","value":45000000,"period":"2026-01","basis_en":"Investment in a JenaValve convertible promissory note","qualifier":null},"note":"에드워즈는 JenaValve 인수계약이 종료된 뒤 2026년 1월 4,500만 달러 규모의 전환사채에 투자했다. 제안했던 9억 4,500만 달러 인수는 법원 가처분 결정 이후 완료되지 않았다.","note_en":"After terminating its JenaValve merger agreement, Edwards invested $45 million in a convertible promissory note in January 2026. The proposed $945 million acquisition was not completed after a court injunction.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-25","url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/ew-20251231.htm","title":"Edwards Lifesciences Corp 10-K (2026-02-25)","title_en":"Edwards Lifesciences Corp 10-K (2026-02-25)","excerpt":"에드워즈는 2026년 1월 JenaValve 전환사채에 4,500만 달러를 투자했다고 공시했다.","excerpt_en":"In January 2026, the Company invested in a convertible promissory note of $45.0 million."},{"stance":"mentions","publisher":"미국 연방거래위원회","publisher_en":"U.S. Federal Trade Commission","kind":"news","lang":"en","published_at":"2025-08-06","url":"https://search.ftc.gov/news-events/news/press-releases/2025/08/ftc-challenges-anticompetitive-medical-device-deal","title":"FTC Challenges Anticompetitive Medical Device Deal","title_en":"FTC Challenges Anticompetitive Medical Device Deal","excerpt":"FTC는 에드워즈가 JenaValve를 9억 4,500만 달러에 인수하려던 거래를 확인했다.","excerpt_en":"Its proposed $945 million acquisition of JenaValve would combine the only two companies with ongoing U.S. clinical trials."}]},{"direction":"investor","counterparty":"스테이트 스트리트","counterparty_slug":"state-street","confidence":"high","metric":{"type":"count","unit":"shares","as_of":"2026-03-31","basis":"스테이트 스트리트의 에드워즈 보통주 13F 보유량","value":26296399,"period":"2026Q1","basis_en":"State Street's Form 13F holding of Edwards common stock","qualifier":null},"note":"스테이트 스트리트는 2026년 3월 31일 기준 에드워즈 보통주 2,629만 6,399주를 보유했다고 SEC 13F에 보고했다. 공시된 보유가치는 약 21억 580만 달러다.","note_en":"State Street reported holding 26,296,399 Edwards common shares as of March 31, 2026, in its SEC Form 13F. The reported position was valued at approximately $2.106 billion.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-05-15","url":"https://www.sec.gov/Archives/edgar/data/93751/000009375126000315/xslForm13F_X02/XML_Infotable.xml","title":"State Street Corporation Form 13F Information Table for 2026 Q1","title_en":"State Street Corporation Form 13F Information Table for 2026 Q1","excerpt":"13F 정보표는 에드워즈 보통주 2,629만 6,399주 보유를 보고했다.","excerpt_en":"EDWARDS LIFESCIENCES CORP, common stock, 26,296,399 shares."}]},{"direction":"revenue","counterparty":"서울아산병원","counterparty_slug":null,"confidence":"high","metric":{"type":"revenue_share","unit":"percent","as_of":"2019-03-01","basis":"서울아산병원 TAVR 치료 중 에드워즈 풍선확장형 판막 사용 비중 하한","value":90,"period":"2019-03","basis_en":"Lower bound of Edwards balloon-expandable valve use in Asan Medical Center TAVR procedures","qualifier":"at_least"},"note":"서울아산병원은 2019년 병원 자료에서 TAVR 치료의 90% 이상에 에드워즈의 풍선확장형 판막을 사용한다고 밝혔다. 병원의 에드워즈 제품 구매액은 공개되지 않았다.","note_en":"Asan Medical Center said in a 2019 hospital publication that Edwards balloon-expandable valves were used in more than 90% of its TAVR procedures. The hospital did not disclose its spending on Edwards products.","sources":[{"stance":"confirms","publisher":"서울아산병원 심장병원","publisher_en":"Asan Medical Center Heart Institute","kind":"ir","lang":"ko","published_at":"2019-03-01","url":"https://www.amc.seoul.kr/asan/depts/heart/K/bbsDetail.do?contentId=265097&menuId=4634","title":"경피적 대동맥판막 치환술(TAVR)","title_en":"Transcatheter Aortic Valve Replacement (TAVR)","excerpt":"서울아산병원에서는 90% 이상의 치료에서 에드워드 풍선 확장 판막을 사용하고 있습니다.","excerpt_en":"Asan Medical Center uses Edwards balloon-expandable valves in more than 90% of treatments."}]},{"direction":"investor","counterparty":"BlackRock","counterparty_slug":"blackrock","confidence":"high","metric":{"type":"share","unit":"percent","as_of":"2025-09-30","basis":"BlackRock의 에드워즈 실질 보유 지분율","value":7.5,"period":"2025-09-30","basis_en":"BlackRock beneficial ownership of Edwards","qualifier":null},"note":"BlackRock은 2025년 9월 30일 기준 에드워즈 보통주 4,426만 7,376주를 실질 보유해 지분율 7.5%를 기록했다. BlackRock의 Schedule 13G/A와 에드워즈의 2026년 위임장 공시가 같은 수치를 확인한다.","note_en":"BlackRock beneficially owned 44,267,376 Edwards common shares, or 7.5%, as of September 30, 2025. BlackRock's Schedule 13G/A and Edwards' 2026 proxy statement report the same position.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-03-26","url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm","title":"Edwards Lifesciences Corporation 2026 Proxy Statement","title_en":"Edwards Lifesciences Corporation 2026 Proxy Statement","excerpt":"위임장 공시는 BlackRock의 실질 보유량을 4,426만 7,376주, 7.5%로 기재했다.","excerpt_en":"BlackRock, Inc.: 44,267,376 shares, 7.5% of the class."},{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2025-10-17","url":"https://www.sec.gov/Archives/edgar/data/1099800/000201238325002528/xslSCHEDULE_13G_X01/primary_doc.xml","title":"BlackRock Schedule 13G/A for Edwards Lifesciences","title_en":"BlackRock Schedule 13G/A for Edwards Lifesciences","excerpt":"BlackRock은 에드워즈 주식 4,426만 7,376주, 7.5%를 실질 보유했다고 신고했다.","excerpt_en":"Aggregate amount beneficially owned: 44,267,376; percent of class: 7.5%."}]},{"direction":"revenue","counterparty":"NHS Supply Chain","counterparty_slug":null,"confidence":"high","metric":{"type":"contract_value","unit":"GBP","as_of":"2025-06-20","basis":"NHS 구조적 심장 및 심실보조장치 프레임워크의 에드워즈 몫","value":null,"period":"2025-06-20/2027-06-19","basis_en":"Edwards share of the NHS structural-heart and ventricular-assist-device framework","qualifier":"confirmed_no_disclosed_value"},"note":"영국 NHS Supply Chain은 2025년 6월 시작한 구조적 심장 및 심실보조장치 조달 프레임워크의 공급자로 에드워즈를 선정했다. 에드워즈 제품은 NHS의 전자조달 경로에서 구매할 수 있지만 회사별 계약 금액은 공개되지 않았다.","note_en":"NHS Supply Chain selected Edwards for its structural-heart and ventricular-assist-device procurement framework beginning in June 2025. Edwards products can be purchased through the NHS eDirect route, but the supplier-specific contract value was not disclosed.","sources":[{"stance":"confirms","publisher":"NHS Supply Chain","publisher_en":"NHS Supply Chain","kind":"filing","lang":"en","published_at":"2025-06-20","url":"https://www.supplychain.nhs.uk/product-information/contract-launch-brief/structural-heart-and-ventricular-assist-devices/","title":"Structural Heart and Ventricular Assist Devices","title_en":"Structural Heart and Ventricular Assist Devices","excerpt":"프레임워크 공급자 목록에 Edwards Lifesciences Ltd가 포함됐다.","excerpt_en":"There are 10 suppliers on this framework, including Edwards Lifesciences Ltd."}]},{"direction":"cost","counterparty":"Vernay Laboratories","counterparty_slug":null,"confidence":"mid","metric":{"type":"amount","unit":"USD","as_of":"2025-12-17","basis":"Vernay와의 부품 조달 거래액","value":null,"period":"2025","basis_en":"Component procurement value with Vernay","qualifier":"confirmed_no_disclosed_value"},"note":"Vernay Laboratories는 유량제어용 정밀 엘라스토머 부품을 만드는 에드워즈의 핵심 공급사다. 2025년 에드워즈 공급사상을 받았지만 거래 금액은 공개되지 않았다.","note_en":"Vernay Laboratories supplies Edwards with precision elastomeric flow-control capabilities and is described as a key supplier. It received an Edwards supplier award in 2025, but transaction value was not disclosed.","sources":[{"stance":"confirms","publisher":"Vernay Laboratories","publisher_en":"Vernay Laboratories","kind":"news","lang":"en","published_at":"2025-12-17","url":"https://vernay.com/news-and-events/vernay-laboratories-receives-edwards-lifesciences-supplier-award-for-world-class-performance/","title":"Vernay Laboratories Receives Edwards Lifesciences Supplier Award for World-Class Performance","title_en":"Vernay Laboratories Receives Edwards Lifesciences Supplier Award for World-Class Performance","excerpt":"에드워즈 공급망 책임자는 Vernay를 회사 수요를 충족하는 핵심 공급사로 설명했다.","excerpt_en":"The recognition underscores Vernay's reliability and performance as a key supplier."}]},{"direction":"cost","counterparty":"Secant Group","counterparty_slug":null,"confidence":"mid","metric":{"type":"amount","unit":"USD","as_of":"2023-02-01","basis":"Secant Group 이식형 섬유 부품 조달액","value":null,"period":"2022","basis_en":"Procurement value for Secant Group implantable textile components","qualifier":"confirmed_no_disclosed_value"},"note":"Secant Group은 에드워즈 의료기기에 들어가는 이식형 의료용 섬유 부품을 공급해 왔다. 에드워즈는 이 회사를 2022년 올해의 공급사로 선정했지만 구매액은 공개하지 않았다.","note_en":"Secant Group has supplied implantable medical-textile components used in Edwards devices. Edwards named it 2022 Supplier of the Year, but procurement value was not disclosed.","sources":[{"stance":"confirms","publisher":"Secant Group","publisher_en":"Secant Group","kind":"news","lang":"en","published_at":"2023-02-01","url":"https://secant.com/edwards-lifesciences-awards-secant-group-2022-supplier-of-the-year/","title":"Edwards Lifesciences Awards Secant Group 2022 Supplier of the Year","title_en":"Edwards Lifesciences Awards Secant Group 2022 Supplier of the Year","excerpt":"Secant는 에드워즈 의료기기를 위한 이식형 섬유 솔루션의 장기 공급 관계를 밝혔다.","excerpt_en":"We're proud to be a long-serving partner of Edwards."}]},{"direction":"cost","counterparty":"Supercomal Medical Products","counterparty_slug":null,"confidence":"mid","metric":{"type":"amount","unit":"USD","as_of":"2022-09-29","basis":"Supercomal Medical Products와의 조달 거래액","value":null,"period":"2021","basis_en":"Procurement value with Supercomal Medical Products","qualifier":"confirmed_no_disclosed_value"},"note":"Supercomal Medical Products는 에드워즈의 의료기기 공급사이며 2021년 700곳이 넘는 공급사 가운데 올해의 공급사로 선정됐다. TA Securities 리포트가 관계를 확인하지만 상대별 거래액은 제시하지 않았다.","note_en":"Supercomal Medical Products supplies medical-device products to Edwards and was named Supplier of the Year for 2021 from a pool of more than 700 vendors. A TA Securities report confirms the relationship but does not disclose transaction value.","sources":[{"stance":"confirms","publisher":"TA Securities","publisher_en":"TA Securities","kind":"research","lang":"en","published_at":"2022-09-29","url":"https://cdn1.i3investor.com/my/files/st88k/0001_SCOMNET/pt/TA/0001_SCOMNET_TA_2022-09-29_BUY_2.00_SupercomnetTechnologiesBerhadAHighQualitySupplierofMedicalDevices_154244764.pdf","title":"Supercomnet Technologies Berhad: A High Quality Supplier of Medical Devices","title_en":"Supercomnet Technologies Berhad: A High Quality Supplier of Medical Devices","excerpt":"리포트는 Supercomal이 에드워즈의 700여 공급사 중 2021년 올해의 공급사로 선정됐다고 밝혔다.","excerpt_en":"SMP was awarded supplier of the year 2021 by Edwards Lifesciences."}]}]}